Mukka Proteins Approves Q1 FY27 Results, Reappoints Directors, Invests in SESPL
Mukka Proteins approved Q1 FY27 results. Consolidated revenue was ₹489.65 crore, with PAT ₹18.63 crore. Standalone revenue was ₹405.86 crore, with PAT ₹19.41 crore. The company will hold its AGM on Sep 10, 2026. It will invest ₹64.92 lakh in Swachha Eco Solutions and reappointed key directors and management for five-year terms starting Jan 2027.
The outcome of the board meeting includes financial results, a strategic investment, and reappointment of key management and directors, all of which are material events for the company.
The company reported its financial results, approved strategic investments, and reappointed key management and directors, indicating stability and forward-looking plans.
Mukka Proteins Limited announced the outcome of its Board Meeting held on August 12, 2026. The Board approved the unaudited financial results (standalone and consolidated) for the quarter and three months ended June 30, 2026. The 16th Annual General Meeting (AGM) is scheduled for September 10, 2026, at 3:00 p.m. via Video Conferencing/Other Audio-Visual Means.
Key decisions also included the cancellation and withdrawal of the proposed issuance of Non-Convertible Debentures worth up to ₹75 crore. Furthermore, the company approved an investment of ₹64,92,500 in Swachha Eco Solutions Private Limited (SESPL), acquiring a 25.98% stake and making SESPL an associate.
The Board also approved the re-appointment of several key personnel, subject to shareholder approval at the ensuing AGM. Mr. Karkala Shankar Balachandra Rao, Mr. Hamad Bava, and Mr. Narendra Surendra Kamath were re-appointed as Non-Executive Independent Directors for a second term of five years from January 15, 2027, to January 14, 2032. Mr. Kalandan Mohammed Haris was re-appointed as Managing Director and CEO for five years from January 20, 2027, to January 19, 2032. Additionally, Mr. Kalandan Mohammed Althaf was re-appointed as Whole-Time Director and CFO, and Mr. Kalandan Mohammad Arif as Whole-Time Director and COO, both for five-year terms commencing January 20, 2027, to January 19, 2032.
The financial results for the quarter ended June 30, 2026, show total consolidated revenue from operations of ₹4,896.54 million and a profit after tax of ₹186.34 million. Standalone revenue from operations was ₹4,058.56 million with a profit after tax of ₹194.07 million.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.